Hanumaiah Telikepalli

Title: Hanumaiah Telikepalli: Innovator in Anti-Cancer Compounds

Introduction

Hanumaiah Telikepalli is a notable inventor based in Lawrence, KS (US). He has made significant contributions to the field of medicinal chemistry, particularly in the development of compounds that exhibit anti-cancer and anti-proliferative activities. His work is crucial in the ongoing fight against cancer and other serious diseases.

Latest Patents

Hanumaiah holds a patent for "1,2,4-triazol-5-ones and analogs exhibiting anti-cancer and anti-proliferative activities." This patent describes compounds of Formula I that are useful in treating cancer, autoimmune diseases, and metabolic bone disorders. These compounds work through the inhibition of c-FMS (CSF-1R), c-KIT, and/or PDGFR kinases. Additionally, they have potential applications in treating other mammalian diseases mediated by these kinases. He has 1 patent to his name.

Career Highlights

Hanumaiah is currently employed at Deciphera Pharmaceuticals, LLC, where he continues to innovate and develop new therapeutic compounds. His work at Deciphera is instrumental in advancing the company's mission to create transformative medicines for patients with cancer and other serious diseases.

Collaborations

Throughout his career, Hanumaiah has collaborated with esteemed colleagues, including Daniel L Flynn and Gary E L Brandt. These collaborations have enhanced his research and contributed to the development of effective treatments.

Conclusion

Hanumaiah Telikepalli is a dedicated inventor whose work in anti-cancer compounds is making a significant impact in the medical field. His innovative research continues to pave the way for new treatments that can improve patient outcomes.